Royal DSM NA Chief Executive Officer Feike Sijbesma, who spent $3 billion making the world’s largest vitamin producer, now nurses solar panel and medical-implant investments to supplement a slower-growth materials unit.
Novartis AG’s animal-health business is drawing interest from drugmakers including Eli Lilly & Co. and Merck & Co. as the Swiss pharmaceutical giant prepares to sell the unit, people with knowledge of the matter said.
Oasmia Pharmaceutical AB rose the most in more than three months after the biotechnology company said its manufacturing plant in Sweden passed a pre-approval inspection by the U.S. Food and Drug Administration.
Hilton Worldwide Holdings Inc., the world’s largest hotel operator, plans to increase its U.S. initial public offering to about $2.25 billion to allow preferred shareholders to sell about $1 billion of stock, according to people with knowledge of the situation.
Davis Polk & Wardwell LLP advised Shire Plc, which agreed to buy ViroPharma Inc. for about $4.2 billion to gain treatments for rare diseases and lessen dependence on its best-selling Vyvanse pill for attention deficit hyperactivity disorder. Skadden, Arps, Slate, Meagher & Flom LLP advised ViroPharma.